E Pons-Tostivint1, L Daubisse-Marliac2, P Grosclaude3, E Oum Sack4, J Goddard4, C Morel4, C Dunet4, L Sibrac5, C Lagadic3, E Bauvin4, Y Bergé6, C Bernard-Marty7, C Vaysse8, J L L Lacaze5. 1. Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France; Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France. Electronic address: elvire.pons-tostivint@inserm.fr. 2. Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, F-31059, France; LEASP, UMR 1027 Inserm, Université de Toulouse III, F-31000, France. 3. Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, F-31059, France. 4. Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France. 5. Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France. 6. Department of Medical Oncology, Clinique Claude-Bernard, Albi, France. 7. Department of Medical Oncology, ONCORAD, Clinique Pasteur, Toulouse, France. 8. Toulouse University Hospital Center (CHU Toulouse), IUCT-Oncopole, 31000, Toulouse, France.
Abstract
INTRODUCTION: We evaluate breast cancer (BC) pathway at a regional level including public, private and university institutions. We assessed the quality of multidisciplinary team meetings (MTM) and compliance with a panel of European high-quality indicators (EUSOMA QIs). METHODS: We conducted a retrospective multicenter (n = 20) study in the largest health care region in France. Between January and April 2015, we included all patients discussed at an MTM after a diagnosis of BC (n = 619). We analyzed quality of MTM by assessing the quorum, the reliability of data transcription and the exhaustivity of pre-therapeutic MTM. We then analyzed the compliance with a selected panel of 16 EUSOMA QIs. RESULTS: During MTM discussion, data were more than 95% consistent with medical records for 9/11 items. Pre-operative tumor histology (90.6%) and post-operative resection margins (84.3%) were the least concordant between medical records and MTM. Minimum standards as defined by EUSOMA were reached for 11/16 QIs, but not reached for pathology reports in non-invasive BC (78.2%), proportion of exclusive sentinel lymph node biopsies in patients with clinically negative axilla (85.2%), performing adjuvant chemotherapy (76.6%), and proportion of patients discussed in pre-therapeutic and post-operative MTM (63.5%). CONCLUSIONS: In this multicentric study evaluating the quality of BC care with a representative sample of institutions, compliance with EUSOMA indicators was satisfactory for all type of institutions. However, too few patients were discussed in pre-therapeutic MTM (especially in non-university hospitals 43.7% [39.4-48.1]) versus 88.7% for others [82.2-95.1]) and data transcription was likely responsible for up to 15% of discordance.
INTRODUCTION: We evaluate breast cancer (BC) pathway at a regional level including public, private and university institutions. We assessed the quality of multidisciplinary team meetings (MTM) and compliance with a panel of European high-quality indicators (EUSOMA QIs). METHODS: We conducted a retrospective multicenter (n = 20) study in the largest health care region in France. Between January and April 2015, we included all patients discussed at an MTM after a diagnosis of BC (n = 619). We analyzed quality of MTM by assessing the quorum, the reliability of data transcription and the exhaustivity of pre-therapeutic MTM. We then analyzed the compliance with a selected panel of 16 EUSOMA QIs. RESULTS: During MTM discussion, data were more than 95% consistent with medical records for 9/11 items. Pre-operative tumor histology (90.6%) and post-operative resection margins (84.3%) were the least concordant between medical records and MTM. Minimum standards as defined by EUSOMA were reached for 11/16 QIs, but not reached for pathology reports in non-invasive BC (78.2%), proportion of exclusive sentinel lymph node biopsies in patients with clinically negative axilla (85.2%), performing adjuvant chemotherapy (76.6%), and proportion of patients discussed in pre-therapeutic and post-operative MTM (63.5%). CONCLUSIONS: In this multicentric study evaluating the quality of BC care with a representative sample of institutions, compliance with EUSOMA indicators was satisfactory for all type of institutions. However, too few patients were discussed in pre-therapeutic MTM (especially in non-university hospitals 43.7% [39.4-48.1]) versus 88.7% for others [82.2-95.1]) and data transcription was likely responsible for up to 15% of discordance.
Authors: Gábor Rubovszky; Judit Kocsis; Katalin Boér; Nataliya Chilingirova; Magdolna Dank; Zsuzsanna Kahán; Dilyara Kaidarova; Erika Kövér; Bibiana Vertáková Krakovská; Károly Máhr; Bela Mriňáková; Béla Pikó; Ivana Božović-Spasojević; Zsolt Horváth Journal: Pathol Oncol Res Date: 2022-07-11 Impact factor: 2.874